Stock Groups

AstraZeneca hopeful its antibody cocktail will work on new COVID variant -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – Test tubes seen in front a AstraZeneca logo. Illustration taken on May 21, 2021. REUTERS/Dado Ruvic/Illustration

LONDON (Reuters: AstraZeneca, NASDAQ:), said Friday that its antibodies against COVID-19 were likely to continue working against a new South African variant. They also examined whether it could be resistant.

AstraZeneca stated that it is investigating B.1.1.529 as a new variant. It also added that it was doing research in Botswana to gather data.

We are currently testing our long-acting combination of antibodies AZD7442 with this variant. We are optimistic that AZD7442’s efficacy will be maintained as it contains two powerful antivirals, each having different and complementary activity against the virus.”

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts, buy/sell signal, and quotes. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]